The abstract is read at the publisher; the summary is JClub's.
In AGS gastric adenocarcinoma cells, PI3K inhibition combined with MEK or TAK1 inhibition shows synergy that concentrates at pathway convergence nodes, amplifying growth and survival control.
- Why it matters: Targeted kinase inhibitors often produce only transient or incomplete responses, and it is unclear whether combination synergy comes from new signalling programs or from reinforcing shared downstream control points.
- What they did: The study used time-resolved phosphoproteomics and transcriptomics after single-agent and combination treatments, spanning 30 minutes to 24 h, and decomposed responses into monotherapy-like versus combination-specific components.
- The result: Global phosphorylation and gene-expression changes largely matched monotherapies, while synergy was linked to stronger suppression of MYC-linked proliferative programs and CREB1-associated survival signalling, plus unique repression of nucleotide metabolism and aminoacyl-tRNA biosynthesis consistent with reduced mTOR activity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.